You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Matador Capital Partners | 0 | 423,000 | 0 | 423,000 | 423,000 | 17.03% |
BFK Investments | 0 | 423,000 | 0 | 423,000 | 423,000 | 17.03% |
Jeffrey A. Berg | 10,600 | 10,600 | 423,000 | 433,600 | 17.46% |
Page 1 of 8 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No. 9)
NTN
Buzztime, Inc.
(Name
of Issuer)
Common
Stock, par value $.005 per share
(Title
of Class of Securities)
629410606
(CUSIP
Number)
Jeffrey
A. Berg
603
N. Indian River Drive
Suite
300
Ft.
Pierce, FL 34950
(760)
438-7400
(Name,
Address and Telephone Number of Person
Authorized
to Receive Notices and Communications)
March
31, 2017
(Date
of Event Which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box. [ ]
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
section 240.13d-7 for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
Potential
persons who are to respond to the collection of information contained in this form are not required to respond unless the form
displays a currently valid OMB control number.
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 2 of 8 – SEC Filing
1. | Names of Reporting Persons | |
Matador Capital Partners, L.P. | ||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) | [ ] | |
(b) | [X] | |
3. | SEC Use Only | |
4. | Source of Funds (See Instructions) | WC |
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ____ | |
6. | Citizenship or Place of Organization | Delaware |
Number Shares Beneficially Owned Each Person | 7. | Sole Voting Power | 0
|
8. | Sh1red Voting Power | 423,000 | |
| |||
9. | Sole
| 0 | |
10. | Shared Dispositive Power | 423,000 | |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person | 423,000 |
12. | Check
| _______ |
13. | Percent
| 17.03% |
14. | Type
| PN |
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 3 of 8 – SEC Filing
1. | Names of Reporting Persons | |
BFK Investments LLC | ||
2. | Check the Appropriate Box if a Member of a Group (See Instructions | |
(a) | [ ] | |
(b)
| [X] | |
3. | SEC
| |
4. | Source of Funds (See Instructions) | AF |
5. | Check
| |
6. | Citizenship
| Florida |
Number Shares Beneficially Owned Each Person | 7. | Sole Voting Power | 0 |
8. | Shared Voting Power | 423,000 | |
9. | Sole Dispositive Power | 0 | |
10. | Shared Dispositive Power | 423,000 | |
11. | Aggregate
| 423,000 |
12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | ________ |
| ||
13. | Percent of Class Represented by Amount in Row (11) | 17.03% |
| ||
14. | Type
| OO |
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 4 of 8 – SEC Filing
1. | Names of Reporting Persons | |
Jeffrey
| ||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) | [ ] | |
(b)
| [X] | |
3. | SEC Use Only | |
4. | Source of Funds (See Instructions) | AF, PF |
5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ____ | |
6. | Citizenship
| U.S. |
Number Shares Beneficially Owned Each Person | 7. | Sole Voting Power | 10,600 |
8. | Shared Voting Power | 423,000 | |
9. | Sole Dispositive Power | 10,600 | |
10. | Shared Dispositive Power | 423,000 | |
11. | Aggregate Amount Beneficially Owned by Each Reporting Person | 433,600 |
12. | Check
| ______ |
13. | Percent of Class Represented by Amount in Row (11) | 17.46%
|
14. | Type of Reporting Person (See Instructions) | IN, HC |
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 5 of 8 – SEC Filing
Pursuant
to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 9 to Schedule 13D (this “Amendment
No. 9”) amends the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”)
on September 29, 2008 (the “Original Schedule 13D”), as amended by the amendments thereto previously filed
with the SEC on the dates indicated below (the Original Schedule 13D, as amended through and including this Amendment No. 9 are
collectively referred to herein as the “Schedule 13D”):
Amendment No. | Filing Date | |
1 | December 19, 2008 | |
2 | January 14, 2011 | |
3 | January 14, 2011 | |
4 | March 7, 2012 | |
5 | September 13, 2012 | |
6 | December 27, 2012 | |
7 | April 21, 2014 | |
8 | November 4, 2016 |
The
Schedule 13D relates to the shares of Common Stock (the “Stock”) of NTN Buzztime, Inc. (the “Issuer”)
owned by Matador Capital Partners, L.P. (the “Fund”), BFK Investments LLC (“BFK”), the general
partner of the Fund, and Jeffrey A. Berg, the Managing Member of BFK. The Fund, BFK and Jeffrey A. Berg are collectively referred
to herein as the “Reporting Persons”. Except as specifically amended by this Amendment No. 9, items in the
Schedule 13D are unchanged.
This
Amendment No. 9 reports a decrease in the Reporting Persons’ percentage of beneficial ownership of the outstanding shares
of Stock since the date the Reporting Persons’ last filing on Schedule 13D as a result of the Issuer’s issuance of
200,000 shares of Stock in connection with a registered direct offering that the Issuer completed on March 31, 2017 (the “March
2017 Offering”). None of the Reporting Persons acquired any shares of Stock in the March 2017 Offering.
Information
in this Amendment No. 9 with respect to each of the Reporting Persons is given solely by that particular Reporting Person, and
none of the other Reporting Persons has any responsibility for the accuracy or completeness of information with respect to any
other Reporting Person. Capitalized terms used herein that are not defined herein have the meanings ascribed to them in the Schedule
13D.
Item
3. Source and Amount of Funds or Other Consideration
The
information provided in Item 5 of this Amendment No. 9 is incorporated by reference to this Item 3.
Item
3 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:
In
November 2016, the Fund purchased 5,620 shares of Stock reported in Item 5 of this Amendment No. 9 using its working capital.
The aggregate purchase price was $40,679.
Item
5. Interest in Securities of the Issuer
Paragraphs
(a), (b) and (d) of Item 5 of the Schedule 13D are hereby amended by replacing them in their entirety with the following:
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 6 of 8 – SEC Filing
(a),
(b) & (d): Each Reporting Person’s beneficial ownership of the Stock on the date of this Amendment No. 9 is reflected
on that Reporting Person’s cover page of this Amendment No.9. The percentage of shares owned by the Reporting Persons is
based upon 2,483,892 shares of Stock outstanding, which is the number of shares outstanding immediately after the March 2017 Offering,
as reported in the Issuer’s filings with the SEC. BFK is a limited liability company and serves as the general partner of
the Fund with the power to invest in, vote and dispose of the Stock on behalf the Fund. The Fund has the right to receive or the
power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Only Mr. Berg as a limited partner
in the Fund individually has an interest through the Fund in more than 5% of the outstanding Stock. Mr. Berg is the Managing Member
of BFK and controls the investment decisions of BFK and the Fund. The Reporting Persons are filing the Schedule 13D jointly, but
not as members of a group, and each of them expressly disclaims membership in a group. Each of BFK and Mr. Berg disclaims beneficial
ownership of the Stock except to the extent of that Reporting Person’s pecuniary interest therein. In addition, the filing
of the Schedule 13D on behalf of the Fund should not be construed as an admission that any of the other Reporting Persons is,
and each of them disclaims that it is, the beneficial owner, as defined in Rule 13d-3 under the Securities Exchange Act of 1934,
of any of the Stock covered by the Schedule 13D.
Paragraph
(c) of Item 5 of the Schedule 13D is hereby amended by the addition of the following:
(c)
The following sets forth all transactions with respect to Shares effected by the Reporting Persons since their last filing on
Schedule 13D: In November 2016, the Fund purchased 5,620 shares of Stock using its working capital, the aggregate purchase price
for which was $40,679. Except as otherwise noted above, all such transactions were purchases of Shares effected in the open market,
and the purchase price includes commissions paid.
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 7 of 8 – SEC Filing
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: March 31, 2017 | MATADOR CAPITAL PARTNERS, L.P. | ||
By: | Name: | BFK Investments LLC | |
Title: | General Partner | ||
By: | /s/ Jeffrey A. Berg | ||
Name: | Jeffrey A. Berg | ||
Title: | Managing Member | ||
Dated: March 31, 2017 | BFK INVESTMENTS LLC | ||
By: | /s/ Jeffrey A. Berg | ||
Name: | Jeffrey A. Berg | ||
Title: | Managing Member |
Dated: March 31, 2017 | JEFFREY A. BERG |
/s/ Jeffrey A. Berg | |
Jeffrey A. Berg |
The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner
of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)
Page 8 of 8 – SEC Filing